- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Risk management plan.
Displaying page 1 of 3.
EudraCT Number: 2017-005010-59 | Sponsor Protocol Number: THERAG0001 | Start Date*: 2018-05-17 |
Sponsor Name:Theragnostics Ltd | ||
Full Title: A Phase II, Open-label Study to Assess Safety and Clinical Utility of 68Ga-THP-PSMA PET/CT in Patients with High Risk Primary Prostate Cancer or Biochemical Recurrence after Radical treatment | ||
Medical condition: High Risk Primary Prostate Cancer or Biochemical Recurrence after Radical treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005008-32 | Sponsor Protocol Number: ICORG13-17 | Start Date*: 2014-07-16 |
Sponsor Name:Cancer Trials Ireland | ||
Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma | ||
Medical condition: Newly diagnosed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001344-11 | Sponsor Protocol Number: CCD-GPLSCD01-03-FU | Start Date*: 2018-04-11 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium i... | |||||||||||||
Medical condition: corneal lesions with associated moderate to severe limbal stem cell deficiency due to ocular burns | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006026-28 | Sponsor Protocol Number: A3481066 | Start Date*: 2006-09-25 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy | |||||||||||||
Medical condition: Patients who are scheduled to undergo routine radical prostatectomy performed under a standardized regimen of general anesthesia, and who are expected to experience moderate to severe postsurgical ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003724-23 | Sponsor Protocol Number: GI-AU-NMH-2016-01 | Start Date*: 2017-12-28 | |||||||||||
Sponsor Name:The George Institute for Global Health, University of New South Wales | |||||||||||||
Full Title: Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial | |||||||||||||
Medical condition: Patients with a history of acute stroke due to Intracranial Haemorrhage with mild to moderately high blood pressure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000197-30 | Sponsor Protocol Number: UoL001289 | Start Date*: 2018-07-13 |
Sponsor Name:The University of Liverpool | ||
Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia | ||
Medical condition: High Risk Oral Epithelial Dysplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003717-18 | Sponsor Protocol Number: 215226/VIR-7831-5005 | Start Date*: 2021-12-30 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
Full Title: An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovim... | |||||||||||||||||||||||
Medical condition: COVID-19 at high risk of disease progression | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001922-26 | Sponsor Protocol Number: BMI-EU-02-008 | Start Date*: 2006-01-06 |
Sponsor Name:Bioheart, Inc | ||
Full Title: A Phase II, Open-label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCellâ„¢ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Pos... | ||
Medical condition: Patients with congestive heart failure who have had a previous myocardial infarction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003680-10 | Sponsor Protocol Number: AROAPOC3-3001 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002527-21 | Sponsor Protocol Number: AMYPAD-01 | Start Date*: 2018-05-23 |
Sponsor Name:University of Geneva | ||
Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh... | ||
Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022445-20 | Sponsor Protocol Number: CA204006 | Start Date*: 2011-11-08 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma. | |||||||||||||
Medical condition: Untreated Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) BE (Completed) AT (Completed) GR (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001285-10 | Sponsor Protocol Number: CA209-171 | Start Date*: 2015-05-15 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at... | |||||||||||||
Medical condition: Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) DE (Ongoing) FI (Completed) DK (Completed) PT (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) GR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005427-20 | Sponsor Protocol Number: C4601003 | Start Date*: 2022-07-13 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISE... | |||||||||||||
Medical condition: Prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) EE (Prematurely Ended) FI (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003866-14 | Sponsor Protocol Number: B5091007 | Start Date*: 2017-06-15 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | ||||||||||||||||||
Medical condition: Primary C difficile infection (CDI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002990-84 | Sponsor Protocol Number: MOR208C310 | Start Date*: 2021-03-01 | ||||||||||||||||
Sponsor Name:MorphoSys AG | ||||||||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untre... | ||||||||||||||||||
Medical condition: Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004197-42 | Sponsor Protocol Number: CUSP9v3 | Start Date*: 2016-08-02 |
Sponsor Name:University Hospital of Ulm | ||
Full Title: A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for ... | ||
Medical condition: Glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004310-18 | Sponsor Protocol Number: SPL-01-001 | Start Date*: 2019-10-07 | |||||||||||
Sponsor Name:Saving Patients' Lives Medical B.V. | |||||||||||||
Full Title: A confirmatory, prospective, open-label, single-arm, reader-blinded multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unen... | |||||||||||||
Medical condition: newly-diagnosed prostate cancer (PCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Ongoing) NL (Completed) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001462-17 | Sponsor Protocol Number: WSG-AM06 | Start Date*: 2012-03-29 | |||||||||||
Sponsor Name:Westdeutsche Studiengruppe GmbH | |||||||||||||
Full Title: Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer | |||||||||||||
Medical condition: Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002869-18 | Sponsor Protocol Number: | Start Date*: 2019-09-04 | |||||||||||
Sponsor Name:Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression. | |||||||||||||
Medical condition: Bipolar disorder (BD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
